ACP's New Mammogram Guidance Stirs Medical Debate

SAN FRANCISCO, CA – April 17, 2026 – The American College of Physicians (ACP) today issued new breast cancer screening guidance that emphasizes a more individualized approach, recommending biennial mammograms for most women aged 50 to 74 but urging caution and conversation for other age groups. The move signals a significant shift toward weighing the potential harms of screening, such as false positives and overdiagnosis, against its life-saving benefits, sparking immediate and sharp debate within the medical community.

The guidance statement, published in the Annals of Internal Medicine, advises that all asymptomatic, average-risk females should undergo screening mammography every two years between the ages of 50 and 74. However, it diverges from other major guidelines by recommending that women between 40 and 49 engage in a detailed discussion with their doctor about the pros and cons before deciding to begin screening.

"Screening for breast cancer is essential and should be guided by the best available evidence," said Dr. Jason M. Goldman, President of ACP, in a statement accompanying the release. "ACP developed this guidance to provide physicians and females with the information they need to make breast cancer screening decisions, including when to start and discontinue, how often to screen, and which methods to use for screening."

The New Recommendations Explained

The core of the ACP's guidance is a tailored approach based on age and risk. For the 50-to-74 age group, the evidence for biennial screening is considered strong. For women aged 40 to 49, the ACP states that the potential harms—including false-positive results, subsequent psychological distress, overdiagnosis, and unnecessary radiation exposure—may outweigh the uncertain benefits.

"The balance of benefits and harms of screening is more complex in younger women," explained Dr. Carolyn J. Crandall, Chair of the ACP Guidelines Committee. The committee's review found that while screening this group led to a small reduction in breast cancer mortality, it came at the cost of significantly more harms. The ACP estimates that over a decade of annual screening, 50% to 60% of women will experience at least one false-positive result, leading to anxiety and further testing.

The guidance also addresses the other end of the age spectrum, advising that asymptomatic, average-risk women who are 75 or older, or those with a life expectancy of less than 10 years, should discuss stopping routine screening with their doctor. The rationale is that the benefits become less certain with age, while the risk of harms like overdiagnosis—detecting cancers that would never have caused symptoms—increases.

Average risk is defined by the ACP as women without a personal history of breast cancer, a known high-risk genetic mutation like BRCA1 or 2, a familial breast cancer syndrome, or a history of high-dose radiation to the chest at a young age.

A Divided Medical Landscape

The ACP's cautious stance places it at odds with several other prominent medical organizations, creating a confusing landscape for patients and clinicians. The new guidance was immediately met with forceful criticism from the American College of Radiology (ACR) and the Society of Breast Imaging (SBI).

In a joint statement, the ACR and SBI called the ACP's recommendations "outdated and hyperbolic," warning that they "will cause continued confusion among women and could lead to thousands of additional breast cancer deaths each year." These groups argue that delaying screening until age 50 and screening biennially will result in later-stage diagnoses, requiring more aggressive and extensive treatments.

This division highlights a fundamental disagreement in how medical bodies interpret the same body of evidence. The ACR, along with the National Comprehensive Cancer Network (NCCN), continues to recommend annual mammograms for average-risk women starting at age 40. The U.S. Preventive Services Task Force (USPSTF), in a 2024 update, also shifted its own guidance to recommend biennial screening for women starting at age 40, a direct contrast to the ACP's new advice for that decade of life.

Critics of the ACP guidance point out that a significant number of breast cancers, particularly more aggressive forms, are diagnosed in women under 50, and that these cancers disproportionately affect minority women. They argue that a blanket recommendation for shared decision-making in the 40-49 age group may inadvertently discourage screening and widen existing health disparities.

Navigating Patient Choice and Confusion

With major medical organizations offering conflicting advice, the burden of navigating these complex decisions increasingly falls on individual women and their primary care physicians. The ACP's strong emphasis on shared decision-making underscores a broader trend in medicine, moving away from one-size-fits-all mandates toward personalized care.

This means the conversation in the doctor's office is now more critical than ever. For a woman in her 40s, that discussion will need to cover not just her family history but also her personal values regarding the risk of a false positive versus the potential for early detection. For a healthy woman of 76, it will involve weighing the small chance of catching a life-threatening cancer against the higher probability of being treated for a slow-growing tumor that would not have impacted her lifespan.

Physicians are now tasked with translating these differing guidelines into practical advice, a challenge that requires time and clear communication. The ultimate goal, as framed by the ACP, is to ensure that a patient's choice is an informed one, based on a clear understanding of both the life-saving potential of mammography and its very real downsides.

The Dense Breast Dilemma

The ACP's guidance also delves into the complex issue of screening for women with dense breasts, a condition where mammograms are harder to read and cancer can be masked by tissue. For this population, the ACP advises that doctors may consider using supplemental digital breast tomosynthesis (DBT), also known as 3D mammography.

DBT has been shown to find slightly more cancers than traditional 2D mammography in dense tissue. However, the ACP's recommendation is conditional, urging that the decision be based on a discussion of potential harms, radiation exposure, availability, cost, and patient preference.

Notably, the ACP advises against using supplemental MRI or ultrasound for screening average-risk women with dense breasts. The committee concluded that while these tools can find more cancers, they are associated with substantially higher false-positive rates and lead to more biopsies without clear evidence that they reduce mortality in this specific population.

This, too, is a point of contention. Other guidelines, including those from the NCCN and the European Society of Breast Imaging, recommend considering supplemental MRI for women with extremely dense breasts, citing its higher sensitivity. The debate over the best approach for this large subgroup of women highlights the ongoing challenge of refining screening technology and protocols to maximize benefits while minimizing harm.